Recognizing an antigen presented by HLA
TCR-T therapy engineers T cells with a receptor that recognizes an antigen fragment presented on an HLA molecule. This can reach targets derived from proteins inside a cancer cell. Conventional CAR-T instead recognizes a surface target directly. The distinction changes which patients and tumors can be treated.
Why an ordinary tumor panel may not answer the question
The T-cell receptor sees a peptide–HLA combination, not the gene name in isolation. HLA typing and tumor-antigen expression may require separate assays. Being described broadly as “HLA-A2 positive” may still be too imprecise when a product specifies particular alleles. Obtain the original laboratory reports rather than a verbal summary.
Source [1]
Both the HLA type and target must fit
Testing must confirm the required HLA allele and tumor antigen expression using the applicable validated method. A positive antigen result without the right HLA type is insufficient. Age, previous treatment, organ function and ability to undergo cell collection and conditioning also matter.
| Requirement | What it establishes |
|---|---|
| HLA typing | Whether the receptor can recognize an antigen presented by your HLA allele. |
| Tumor antigen test | Whether the target is expressed by the tumor under the required assay. |
| Clinical assessment | Whether prior treatment, disease pace and organ reserve fit the product or protocol. |
Global treatment frontiers
Afamitresgene autoleucel provides an FDA-approved TCR-T example in synovial sarcoma, selected by both HLA type and MAGE-A4 expression. The broader frontier is finding other intracellular targets that distinguish tumor cells from normal tissue.
HBV-related liver cancer offers a different biological opportunity: some tumors retain viral antigens that an engineered T-cell receptor may recognize. Chinese clinical teams have explored HBV-specific TCR-T in carefully selected patients, including recurrence after liver transplantation. The 2025 early studies contribute safety and feasibility evidence, while comparative effectiveness and wider eligibility remain open questions.
A defined approved example
The FDA’s current Tecelra listing covers eligible patients aged 12 years and older with unresectable or metastatic synovial sarcoma after chemotherapy, with specified HLA-A*02 alleles and MAGE-A4-positive tumors. The full product label and companion diagnostic requirements govern selection. This is not a general sarcoma or general solid-tumor approval.
Reports that make the first review useful
- Full pathology with sarcoma subtype, plus the original antigen assay.
- High-resolution HLA report with allele names, not only a broad family label.
- Prior chemotherapy, response and dates; current scans and organ-function results.
- For a research program: exact receptor, protocol and rationale for this cancer.
Treatment demands and risks
Collection, manufacturing, lymphodepletion and infusion require coordinated scheduling. Cytokine release syndrome, infections and prolonged cytopenias are important risks. Recognition of a target also present in healthy tissue, or cross-reactivity with another antigen, is a particular development concern. Ask how the specific receptor has been evaluated and how acute toxicity is managed.
Keep the original HLA and antigen reports. Repeating an unsuitable assay can delay eligibility decisions.
Plan the interval before infusion
A compatible target does not guarantee that a usable product will be manufactured or that the patient will remain fit enough for infusion. Disease progression, infection and unresolved toxicity can change the plan. Review alternative disease control before collection and identify the clinician responsible during the manufacturing interval.
Source [1]
Treatment costs & individual consultation
TCR-T treatment costs depend on the specific program and eligibility assessment, including HLA and tumor-antigen testing, cell collection and preparation, conditioning, infusion and monitoring.
Contact us for an individual cost consultation. Costs can be clarified after treatment suitability, an available pathway and the program’s cost responsibilities have been established. Travel and accommodation are separate.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.